Internet Explorer, Chrome Browser, Firefox Browser, Safari Browser
Press Release12 June 2018Joint Press Release by Siemens and Sartorius Stedim Biotech GmbHFrankfurt
Sartorius Stedim Biotech and Siemens sign long-term cooperation agreement in the area of automation
Sartorius Stedim Biotech has already been using established Siemens automation solutions for process control in its large-scale bioreactor and filtration systems for quite some time. To standardize its own product portfolio even further, SSB has decided to introduce a new, configurable automation system for its range of systems. Under the agreement recently concluded, cooperation between the two companies will therefore be extended to further Sartorius Stedim Biotech products. These will be successively equipped with Siemens automated solutions in the coming months and can thus be integrated into process control systems such as Simatic PCS 7 and Simatic Batch. Essentially, such SSB products are single-use bioreactors of the BIOSTAT STR series, various filtration systems and the FlexAct system. The latter is a flexible module that is used to control many different process steps within biopharmaceutical production.
"By introducing this new automation platform and further standardizing our products, we are making it easy for our customers to integrate their systems into higher-level automation solutions, such as SCADA, MES or ERP. At the same time, we are enabling them to achieve easier scalability of processes ranging from lab scale to commercial-scale production," explained Dr. Oscar-Werner Reif, Chief Technology Officer at Sartorius Stedim Biotech. "We have found an ideal partner in Siemens as one of the leading companies in automation," continued Dr. Reif.
Eckard Eberle, CEO of the Siemens Process Automation business unit, commented: "We are happy to support Sartorius Stedim Biotech with our unique and cohesive portfolio consisting of hardware, software and service throughout the entire system life cycle. Based on our cooperation, users in the biopharmaceutical industry stand to benefit from higher efficiency, quality and flexibility, as well as faster time to market."
During this year's Achema trade show that will be taking place from June 11 to June 15, 2018, in Frankfurt, Germany, Siemens and Sartorius Stedim Biotech will be jointly presenting the FlexAct module, a first product based on the new automation platform. Visitors and all others interested are cordially invited to obtain first-hand information at the Siemens AG booth in Hall 11/C3. A presentation on this product will be held in German on June 12 at 1:30 p.m. and in English on June 13 at 1:00 p.m. and on June 14 at 2:00 p.m.
For further information on Siemens at Achema 2018, please see www.siemens.com/achema and www.siemens.com/press/achema2018
For this press release
Siemens at the Achema 2018
Press Event
Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for 170 years. The company is active around the globe, focusing on the areas of electrification, automation and digitalization. One of the world's largest producers of energy-efficient, resource-saving technologies, Siemens is a leading supplier of efficient power generation and power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. With its publicly listed subsidiary Siemens Healthineers AG, the company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2017, which ended on September 30, 2017, Siemens generated revenue of €83.0 billion and net income of €6.2 billion. At the end of September 2017, the company had around 377,000 employees worldwide. Further information is available on the Internet at www.siemens.com.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of €1,081.0 million. For more information, visit www.sartorius.com.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2017, the company employed approx. 5,100 people, and earned sales revenue of €1,081.0 million. For more information, visit www.sartorius.com.
Contact
David Petry
Siemens AG
Werner-von-Siemens-Str. 65
91052 Erlangen
Germany
91052 Erlangen
Germany
+49 (9131) 7-26616
Dominic Grone
Sartorius Stedim Bio
Otto-Brenner-Str. 20
37079 Goettingen
Germany
37079 Goettingen
Germany
+49 (551) 308 3324